Robotics in every
operating room.
Empowering Every Surgeon. Advancing Every Surgery.
From one robot per hospital to one robot in every operating room.
An unending
span of impact.
Why we exist — and why the name carries the long view of human life and lasting medical impact.
To empower every surgeon and advance every surgery by making surgical robotics deployable at operating-room scale and accessible to more patients.
"Aevum" — Latin for an age, an unending span of time. The name evokes longevity, the long view of human life, and lasting medical impact.
Surgical robotics is stuck
at the top of the market.
Current platforms are large and complex, with substantial infrastructure and training requirements. Adoption stays concentrated in top-tier urban hospitals, under-penetrating mid-tier and emerging markets while growth decelerates in mature regions.
Each step: less invasive,
more precise, more accessible.
Today's robotic surgery solved precision, but not accessibility. The next step is to deliver robotic capability through compact, streamlined architecture. Aevum is positioned at this inflection point.
A compact surgical robot.
Radically simplified.
A smaller-footprint system with streamlined architecture, intuitive control and the robotic capabilities surgeons actually need.
Compact by design
A smaller footprint and streamlined architecture designed around operating-room workflow and the patient side.
Intuitive, surgeon-centred
Controls and workflow designed around surgeons and existing clinical practice.
Built for access
Lower capital cost, smaller footprint, shorter training time — robotic capability mid-tier and emerging hospitals can adopt.
Purpose-built
Dexterity and articulation optimized for constrained-access procedures including SILS, TAMIS and NOTES/VNOTES.
Industry 5.0–ready
AI motion guidance, connectivity and surgical data analytics — built in from day one, not bolted on later.
The promise, visible
The form communicates a simpler, more deployable robotic system designed for a wider range of operating rooms.
A clear vision,
designed into every decision.
Robotics in every operating room is the vision. Compactness, lower complexity, less-invasive capability and surgeon-centred workflow are how Aevum intends to achieve it.
From one robot per hospital to one robot in every operating room.
- Robotics in Every Operating Room — make surgical robotics deployable at operating-room scale.
- Compact Architecture — a smaller footprint designed around operating-room realities.
- Lower System Complexity — retain the capabilities surgeons need while reducing unnecessary infrastructure.
- Purpose-Built for Less-Invasive Surgery — optimize dexterity and articulation for constrained access.
- Surgeon-Centred Design — align intuitive control and workflow with existing clinical practice.
The window is open —
and it is open now.
Technology, supply chain, policy and unmet clinical demand are converging at the same moment.
Industry 5.0 momentum
AI, connectivity and human-centric automation are now mainstream.
Mature GBA ecosystem
Miniaturized motors, MCUs, batteries and sensors at production scale across the Greater Bay Area.
Market growth
Surgical robotics growing 15–20% CAGR globally; APAC outpacing the global average.
China policy tailwind
Explicit national support for domestic medtech and surgical robotics.
Patents expiring
Early robotic-surgery patents are expiring — a freedom-to-operate window opens.
Unmet hospital demand
Mid-tier and emerging markets want accessible robotic surgery they can afford and deploy.
From a global market
to a winnable wedge.
TAM / SAM / SOM — suggested as nested circles or a bar chart. Final numbers to be refined.
Global surgical robotics market
[ USD X B in 2026, projected USD Y B by 2030 — to refine ]
APAC + accessible-robotics-focused emerging markets
[ USD X B addressable subset — to refine ]
HK + GBA pilot, years 1–3
[ Specific revenue target — to refine ]
A distinct category —
not a head-to-head competitor.
We don't compete with da Vinci on capability ceiling. We open a distinct category — competing on accessibility, capturing the tier the market leaves unserved.
Intuitive (da Vinci), CMR Surgical (Versius), Medtronic (Hugo), Asensus (Senhance), Distalmotion (Dexter).
MicroPort (Toumai), Edge Medical (MP1000), Shurui Tech, Surgnova.
Compact, simplified, accessible — a distinct category, not a competitor to da Vinci on capability ceiling. Competing on accessibility and capturing the unserved tier of the market.
Capital today,
recurring tomorrow.
Device sales anchor the model; single-use consumables and software & data services build recurring revenue.
- Device sales — capital purchase or per-procedure pricing.
- Single-use instrument tips / consumables — recurring.
- Software & data services — Industry 5.0 modules, future.
- Training & technical support services.
Hong Kong first,
then outward.
A staged roll-out anchored by PolyU × PUTH clinical evidence, expanding from HK to the GBA, mainland China and international.
Hong Kong
Pilot installations, KOL surgeon engagement, regulatory groundwork.
Greater Bay Area
Leveraging PolyU × PUTH clinical evidence; selected mainland hospitals.
Mainland China
NMPA clearance; provincial roll-out; distributor network across Tier 1–2 cities.
International
FDA clearance; US, Southeast Asia, MENA via strategic partners.
Two markets in parallel —
with a lean fallback.
Parallel NMPA + FDA filings where funding allows, with a capital-efficient FDA-first route in reserve. ISO 13485 from day one.
Full funding
Parallel NMPA + FDA filings — capturing both major markets in parallel.
FDA-first · 510(k)
Substantial-equivalence route to minimize cost and time. Predicate device identification is a Phase 1 priority with regulatory counsel.
Later extension
Pursued once US and CN clearances are in hand (considering cash on hand and new CE MDR requirements).
ISO 13485 QMS
Established from day one.
Anchored at one of
China's top hospitals.
PolyU × Peking University Third Hospital — a Medicine-Engineering Collaborative Innovation Research Laboratory, MoU signed January 2025.
PolyU × Peking University Third Hospital (PUTH)
Medicine-Engineering Collaborative Innovation Research Laboratory — MoU signed January 2025.
- PolyU Faculty of Engineering — Prof. H.C. Man (Dean). Aevum partnership in active discussion; proposal in preparation.
- PUTH Department of General Surgery — Prof. Yuan Chunhui (Director). Validation pathway aligned with NMPA strategy.
Top Grade 3A hospital in China; one of 14 national pilot hospitals for high-quality development.
Additional HK and GBA hospital sites added as the program scales.
A clean foundation,
from day one.
All Aevum IP created at Aevum, by Aevum, for Aevum — separate from any prior employer IP.
Created at Aevum
All Aevum IP created at Aevum, by Aevum, for Aevum — separate from any prior employer IP.
- Instrument architecture & ergonomics
- Capstan-driven articulation mechanism
- Motor pack integration & miniaturization
- Surgeon control interface
HK + PCT
HK + PCT international filings to preserve global rights.
FTO analysis
Commissioned early in the seed phase to identify any blocking patents.
Trademarks
Aevum Surgical trademark + product name registrations across target markets.
Patent moat
+ first-mover speed.
Surgical-robotics depth,
award-winning design.
A founding team that has taken surgical robots to clinical trials and won international design awards.
- Director of Industrial Design at a leading HK surgical robotics company.
- 15+ years across medical robotics, UAVs & product innovation; led FDA / NMPA / CE MDR submissions.
- 8+ design patents; 6 international design awards.
- Three PolyU degrees — BEng (Hons), MDes, ongoing Eng.D.
- 12+ years; Loughborough 1st Class Honours.
- Designed flagship surgical product at Precision Robotics.
- Former PolyU Guest Lecturer.
- 30+ years engineering; 8.5+ years in surgical robotics.
- MSc Biomedical Engineering, CUHK.
- PolyU alumnus.
- [ Detailed bio to be added — instrument design, motor pack, capstans, DFM. ]
A capital-efficient bridge
to first-in-human.
The HKD 3M seed triggers the PolyU partnership and unlocks a much larger follow-on funding pipeline.
Pre-revenue to
commercial in five years.
Suggested visual: 5-year revenue + cumulative funding chart — to populate once numbers are agreed. Detailed financial model available on request.
Every dollar pointed
at the MVP demo.
Team runway to the Oct 2026 MVP demo, prototyping, IP, regulatory groundwork and contingency.
Known risks,
deliberate mitigations.
Each principal risk is paired with a concrete mitigation grounded in the team's track record and diversified pathways.
Raising HKD 3M seed.
A capital-efficient bridge that triggers the PolyU partnership and unlocks the much larger follow-on funding pipeline.
Raising HKD 3M seed
- Vehicle: [ SAFE / convertible / priced equity — to define ]
- Closing target: Q3 2026
- Co-investor profile: HK strategic medtech / family office / corporate VC
- Strategic acquisition by major medtech — Medtronic, J&J, Stryker, Olympus, Mindray.
- Or HK / mainland CN IPO.
- Comparable exit: Auris Health acquired by J&J (2019) for USD 3.4B + USD 2.35B in milestones.
Let's build the future
of surgery.
Technical specifications.
Placeholder — to be populated as the MVP architecture is locked.
The regulatory path.
FDA-first via 510(k) with the parallel NMPA option preserved; CE Mark as a later extension.
Alan Kwok — founder.
Director of Industrial Design with a track record of taking surgical robots to clinical trials. Languages: English, Cantonese, Mandarin (all fluent).
Director, Industrial Design — Precision Robotics (HK) Ltd
May 2023–present
- Reports to Founder/CEO; leads 25 engineers across ID, ME, EE, software.
- Built ID department from 5 to 40+ across HK, Suzhou, Shanghai, UK.
- Led 2 surgical robot platforms + 1 endoscope to clinical trials in 24 months.
- 8+ design patents; managed ISO 13485, FDA, NMPA, CE MDR submissions.
Red Dot 2021 & 2025; iF Design 2022; IDA International Design Award 2024; Geneva Gold Medal 2021; HK Awards for Industries 2021; Red Dot 2014 + Honourable Mention 2014/2016 (earlier work).
BEng (Hons), MDes, ongoing Engineering Doctorate; OPUAA Associate Member.
- XDynamics (drone ID, 2016–2018).
- Cathay Pacific Cadet Pilot Programme (2015–2016).
- Konstar Industries (kitchenware ID, 2011–2015 — Red Dot 2014).
- Days Group, Wings Trading (engineering 2007–2011).
References & sources.
Partnership, comparable exit, market research and regulatory references.